Literature DB >> 3234629

Value of indium-111 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation.

G E Crama-Bohbouth1, J W Arndt, A S Peña, H W Verspaget, R T Tjon A Tham, I T Weterman, E K Pauwels, C B Lamers.   

Abstract

The present study was undertaken to determine the value of indium-111 granulocyte scintigraphy in Crohn's disease of the small bowel by comparing the results with those of radiology, endoscopy and surgery. Twenty-one patients with Crohn's disease of the small bowel, 9 patients with Crohn's disease of the colon, 1 patient with both localizations and 8 with ulcerative colitis were studied by indium-111 granulocyte scanning. Eighteen patients had evidence of active small intestinal disease based on clinical, radiologic, and/or endoscopic, and/or histopathological features. Thirteen of them had a true positive scan (sensitivity 72%), but accurate assessment of localization and extent of disease was often difficult. Five patients had a false negative scan and 4 a true negative. No false positive scans were found. The diagnostic accuracy was 77%. In contrast, from 18 patients with colonic disease, 16 had a true positive scan corresponding in localization and extent with standard investigations, 1 patient had a false negative scan (sensitivity 94%), and 1 a true negative (diagnostic accuracy 95%). This study also showed that 3-5 h scanning after injection of indium-111-labeled granulocytes is the optimal timing for this test. The patient's acceptability of this procedure was definitely superior to radiology and endoscopy. In conclusion, this technique has a definite place in evaluating localization and extent of active colonic disease, but it does not replace good small bowel radiology and should not be recommended in the routine diagnostic workup of Crohn's disease of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234629     DOI: 10.1159/000199659

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

1.  Detection of inflammatory lesions with radiolabelled immunoglobulins.

Authors:  D Blok; M von Ogtrop; J W Arndt; J A Camps; R I Feitsma; W Goedemans; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1990

2.  Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes.

Authors:  J W Arndt; M I Grootscholten; R A van Hogezand; G Griffioen; C B Lamers; E K Pauwels
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

3.  Image quality and radiopharmaceutical parameters of indium-111 granulocytes in scintigraphy of inflammatory bowel disease.

Authors:  J W Arndt; G E Crama-Bohbouth; H W Verspaget; D Blok; A S Pena; R T Tham; I T Weterman; C B Lamers; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1989

4.  Technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy in ulcerative colitis and Crohn's disease.

Authors:  M Papós; F Nagy; J Láng; L Csernay
Journal:  Eur J Nucl Med       Date:  1993-09

5.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

6.  Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?

Authors:  G Crama-Bohbouth; A S Pena; I Biemond; H W Verspaget; D Blok; J W Arndt; I T Weterman; E K Pauwels; C B Lamers
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

7.  Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease.

Authors:  T P Mulder; H W Verspaget; A R Janssens; P A de Bruin; A S Peña; C B Lamers
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

8.  Indium scanning in assessment of acute Crohn's disease. A prospective study of sensitivity and correlation with severity of mucosal damage.

Authors:  D Heresbach; J F Bretagne; J L Raoul; A Moisan; L Siproudhis; A Devillers; M Gosselin
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.